Which period featured better antipsychotics and the discovery of risk genes, with a focus on dimensions of dysfunction and neural basis?

Which period featured better antipsychotics and the discovery of risk genes, with a focus on dimensions of dysfunction and neural basis?

• A. 21st century developments
• B. Mid-20th century advancements
• C. 19th century view
• D. Onset in adolescence

Answer: (B)

The period being tested is the era when pharmacotherapy for psychosis made a major leap and researchers began framing symptoms in neurobiological terms. In the mid-20th century, the introduction of chlorpromazine and subsequent antipsychotics revolutionized treatment by providing reliable, more manageable control of psychotic symptoms. This shift allowed clinicians to treat schizophrenia as a medical, brain-based illness and spurred research into how symptoms could be understood along dimensions—positive symptoms like hallucinations and delusions, negative symptoms such as affect flattening and avolition, and cognitive deficits—within neural circuits. That same era laid the groundwork for linking these symptoms to brain systems, particularly dopaminergic pathways in the mesolimbic and mesocortical circuits, which became central to how antipsychotics work and how researchers thought about the neural basis of dysfunction in psychosis. The discovery of risk genes is a major development that followed, built on the neurobiological framework established earlier, but the defining advances in having effective antipsychotics and shifting to a brain-based, dimension-focused view occurred in this mid-20th-century period.

The period being tested is the era when pharmacotherapy for psychosis made a major leap and researchers began framing symptoms in neurobiological terms. In the mid-20th century, the introduction of chlorpromazine and subsequent antipsychotics revolutionized treatment by providing reliable, more manageable control of psychotic symptoms. This shift allowed clinicians to treat schizophrenia as a medical, brain-based illness and spurred research into how symptoms could be understood along dimensions—positive symptoms like hallucinations and delusions, negative symptoms such as affect flattening and avolition, and cognitive deficits—within neural circuits.

That same era laid the groundwork for linking these symptoms to brain systems, particularly dopaminergic pathways in the mesolimbic and mesocortical circuits, which became central to how antipsychotics work and how researchers thought about the neural basis of dysfunction in psychosis. The discovery of risk genes is a major development that followed, built on the neurobiological framework established earlier, but the defining advances in having effective antipsychotics and shifting to a brain-based, dimension-focused view occurred in this mid-20th-century period.